MRPL3 is identified as a prognostic biomarker and therapeutic target in lung adenocarcinoma via a lactylation-disulfidptosis gene signature model and experimental validation
BackgroundLung adenocarcinoma (LUAD), the most prevalent histological subtype of lung cancer, is a leading cause of global cancer mortality. Its pronounced heterogeneity poses a critical challenge, creating an urgent need for reliable biomarkers to accurately predict patient prognosis. Here, we focu...
Збережено в:
| Автори: | , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Frontiers Media S.A.
2026-05-01
|
| Серія: | Frontiers in Immunology |
| Предмети: | |
| Онлайн доступ: | https://www.frontiersin.org/articles/10.3389/fimmu.2026.1772955/full |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|